Immunity vs Journal of Immunology: Which Should You Submit To?

Immunity's impact factor is 26.3; Journal of Immunology's is 5.0 (2024 JCR). This is a more than 5-fold difference and reflects a real tier gap. Immunity sits at the top end of immunology publishing. Journal of Immunology ranks much lower, though it remains a legitimate outlet for immunology research.

In career terms, publishing in Immunity is elite-level prestige. Hiring committees, grant panels, and universities recognize it immediately as a major achievement. Journal of Immunology is respectable but not prestige-defining. Many established immunologists have never published in Immunity and have solid careers with Journal of Immunology and other specialized outlets.

Immunity publishes mechanistic immunology that advances fundamental understanding of immune system function or reveals new principles of immunity. The journal values papers that either: (1) reveal new mechanisms of immune activation, regulation, or dysfunction; (2) identify novel immune cell types or functions; (3) provide unexpected insights into immune responses to disease. Papers must have strong mechanistic rigor and broad significance.

Journal of Immunology publishes the full spectrum of immunology: basic immune mechanisms, translational immunology, clinical immunology, vaccine research, and applied immunology. The journal is inclusive - well-executed studies on any aspect of immunity are welcome, regardless of whether they reveal paradigm-shifting mechanisms.

In practice: A study revealing a new mechanism of T cell activation would be strong for Immunity. A study characterizing T cell responses to a specific antigen would likely be rejected by Immunity as incremental but would be welcome at Journal of Immunology.

Immunity emphasizes core immunology: lymphocyte biology, innate immunity, immune regulation, immune tolerance, and autoimmunity. The journal is most interested in studies that illuminate how immune systems work at a mechanistic level.

Journal of Immunology covers all areas: adaptive immunity, innate immunity, antibodies, vaccines, tumor immunology, immunoinflammation, immunotherapy, infection immunology, and translational immune medicine. The journal is broadly inclusive and values applied immunology as much as fundamental mechanistic studies.

If your research is vaccine development, tumor immunotherapy, or applied immunology, Journal of Immunology is more natural. Immunity tends toward fundamental lymphocyte mechanisms over applications. That said, Immunity does publish impactful applied work if the mechanism is novel and broadly significant.

Immunity editors are extremely selective. Most submissions are desk-rejected. The journal receives thousands of submissions and publishes only a small fraction. Papers that don't meet the "breakthrough" standard are rejected promptly (within 1-3 weeks). However, papers that pass desk review are given serious peer review consideration.

Journal of Immunology editors are permissive. Well-executed immunology research is sent to peer review. The journal will send incremental studies, clinical case series, and applied work to reviewers if it's methodologically sound and contributes to immunology understanding.

In practical terms: Expect high desk-rejection rates at Immunity. Expect that Journal of Immunology will give your work peer review if it's technically solid, even if it's not breakthrough-level.

Immunity: ~10–12% acceptance rate. Among the most selective journals in all of science. Publishing here is a major achievement.

Journal of Immunology: ~40–45% acceptance rate. About 2 out of 5 submitted papers that reach peer review are accepted. This is a reasonable, accessible acceptance rate.

The acceptance rate difference is dramatic and reflects the editorial philosophy gap. Immunity is elite; Journal of Immunology is accessible.

Immunity: 3-5 days to desk decision, with 3-4 weeks to first decision after review in current Manusights canonical data.

Journal of Immunology: Manusights canonical timing remains much slower overall, so the speed advantage described in older copy should not be overstated.

Immunity is slow but thorough. Journal of Immunology is faster and more efficient.

If your research reveals a new mechanism of immunity or identifies a novel immune principle: Target Immunity. This is the journal for breakthrough immunology. Expect high desk-rejection rates, but acceptance means elite status.

If your research is solid mechanistic immunology but not paradigm-shifting: Journal of Immunology is the more realistic choice. Immunity will likely desk-reject it; Journal of Immunology will give it fair peer review.

If your research is vaccine development, immunotherapy, or applied immunology: Journal of Immunology is the better fit. Immunity skews toward fundamental mechanisms.

If your research is translational or clinical immunology: Journal of Immunology is your journal. Immunity publishes translational work only if it's mechanistically novel at the fundamental level.

If your research is T cell or B cell biology with clear implications for immunity: Immunity is worth attempting, especially if your work reveals unexpected mechanisms or cell states.

If you're unsure: Journal of Immunology is the safer choice. It accepts 4x higher percentage of papers and will give your work proper consideration. If your work is truly breakthrough-level, you can try Immunity first, knowing that Journal of Immunology is a strong backup.

If Immunity rejects your mechanistic immunology paper, Journal of Immunology is an excellent second home. The journals don't penalize prior rejection elsewhere. Journal of Immunology editors will evaluate your work independently. Many solid immunology papers are rejected by Immunity and published in Journal of Immunology - that's not a failure; it's a natural outcome of Immunity's extreme selectivity.

Conversely, if Journal of Immunology accepts your paper after Immunity rejection, that's a valid and valuable publication. Your work will reach the immunology community, be cited, and advance the field.

Immunity is the elite journal for breakthrough immunology - mechanistically novel, broadly significant work. Journal of Immunology is the community journal - accessible, inclusive, and broad in scope. Publishing in Immunity is a career-defining achievement; publishing in Journal of Immunology is a solid contribution. Most established immunologists have published in Journal of Immunology. Many have never published in Immunity. Choose Immunity if your work is breakthrough-level; choose Journal of Immunology if you want your work to reach the immunology community with realistic publication odds.

Both journals allow $0 subscription publication. If you choose OA, Immunity's Cell Press pricing (~$9,900) is significantly higher than JI's AAI pricing (~$2,000-$3,000). For labs with OA mandates and limited funding, this cost difference may influence the choice.

If Immunity desk-rejects, the Cell Press transfer system can route your paper to Cell Reports (IF 6.9). Within the broader immunology landscape, Journal of Experimental Medicine (IF 11.7) or Nature Immunology (IF 27.7) are worth considering before defaulting to JI.

Wondering whether your immunology paper clears the bar for Immunity or is better positioned for JI? A Immunity vs. Journal of Immunology scope check can help you decide before you commit to a submission cycle.